PD-1/PD-L1在非小细胞肺癌中的临床研究进展

Research progress on PD-1/PD-L1 in the treatment of non-small cell lung cancer

摘要: 近年来，免疫治疗在癌症研究中取得了突飞猛进的发展。以程序性死亡受体-1（programmed cell death-1，PD-1）及其配体程序性死亡配体-1（programmed cell death-ligand 1，PD-L1）为靶点的免疫治疗药物在非小细胞肺癌（non-small cell lung cancer，NSCLC）的治疗中显示出了良好的疗效和耐受性，治疗前景值得期待。本文对PD-1/PD-L1治疗NSCLC的临床研究现状进行综述。

Abstract: In recent years, immune therapy for the treatment of cancer has made remarkable progress. The monoclonal antibodies of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) have shown considerable responses and good tolerance in the treatment of non-small cell lung cancer (NSCLC). In this review, we summarized the current clinical status and future direction of PD-1/ PD-L1 in NSCLC.